lorazepam has been researched along with Hypertension in 14 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
Excerpt | Relevance | Reference |
---|---|---|
"Sixty-two adults with a current diagnosis of significant hypertension and accompanying moderate to severe anxiety were medicated with lorazepam or with placebo for a period of 4 weeks." | 9.04 | The effect of lorazepam on hypertension-associated anxiety: a double-blind study. ( Hart, WL; Parmley, LF, 1978) |
"Sixty-two adults with a current diagnosis of significant hypertension and accompanying moderate to severe anxiety were medicated with lorazepam or with placebo for a period of 4 weeks." | 5.04 | The effect of lorazepam on hypertension-associated anxiety: a double-blind study. ( Hart, WL; Parmley, LF, 1978) |
" The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
" A reduction in the dosage of benzodiazepines in the setting of epileptic patients with predominant autonomic symptoms may need to be considered." | 1.37 | Benzodiazepines in the acute management of seizures with autonomic manifestations: anticipate complications! ( Fluss, J; Gervaix, A; Korff, CM; Lacroix, L, 2011) |
"We report a case of gamma-hydroxybutyrate (GHB) withdrawal resulting in severe agitation, mental status changes, elevated blood pressure, and tachycardia hours after stopping chronic use of GHB." | 1.31 | Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. ( Bania, TC; Craig, K; Gomez, HF; McManus, JL, 2000) |
"Lorazepam was an effective sedative and anxiolytic by either route, and there were no eclamptic fits among the lorazepam-treated patients." | 1.26 | Effect of maternal lorazepam on the neonate. ( Cummings, AJ; McFadyen, IR; Whitelaw, AG, 1981) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (21.43) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 7 (50.00) | 29.6817 |
2010's | 2 (14.29) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors | Studies |
---|---|
Gouse, BM | 1 |
Spears, WE | 1 |
Nieves Archibald, A | 1 |
Montalvo, C | 1 |
Shah, P | 1 |
McDowell, M | 1 |
Ebisu, R | 1 |
Hanif, T | 1 |
Toerne, T | 1 |
Marchione, P | 1 |
Vento, C | 1 |
Marianetti, M | 1 |
Romeo, T | 1 |
Amabile, GA | 1 |
Giacomini, P | 1 |
Lacroix, L | 1 |
Fluss, J | 1 |
Gervaix, A | 1 |
Korff, CM | 1 |
Maccioli, GA | 1 |
Zeller, A | 1 |
Handschin, D | 1 |
Gyr, N | 1 |
Martina, B | 1 |
Battegay, E | 1 |
Rezvani, M | 1 |
Hartfield, D | 1 |
Jerome, L | 1 |
Smolinske, SC | 1 |
Rastogi, R | 1 |
Schenkel, S | 1 |
Whitelaw, AG | 2 |
Cummings, AJ | 2 |
McFadyen, IR | 1 |
Deckert, J | 1 |
Przuntek, H | 1 |
Gleiter, CH | 1 |
Craig, K | 1 |
Gomez, HF | 1 |
McManus, JL | 1 |
Bania, TC | 1 |
Hart, WL | 1 |
Parmley, LF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)[NCT01362205] | Phase 4 | 49 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to DSMB recommendation for slow enrollment) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Minnesota Detoxification Scale (MINDS) min score 0, max score 46. The higher the score, the worse the symptoms of AWS/AWD. (NCT01362205)
Timeframe: up to 28 days
Intervention | units on a scale (Median) |
---|---|
Dexmedetomidine | 8.2 |
Placebo | 9.4 |
A ventilator day is counted for any use of invasive mechanical ventilation during a calendar day (NCT01362205)
Timeframe: up to 28 days
Intervention | days (Median) |
---|---|
Dexmedetomidine | 27.5 |
Placebo | 28.0 |
(NCT01362205)
Timeframe: Up to 28 days
Intervention | USD (Median) |
---|---|
Dexmedetomidine | 81234 |
Placebo | 91651 |
(NCT01362205)
Timeframe: up to 28 Days
Intervention | Dollar (United States) (Median) |
---|---|
Dexmedetomidine | 3482 |
Placebo | 4461 |
The Beck Anxiety Inventory is a validated questionnaire used to measure severity of anxiety (min score 0, max score 63). The higher the score the greater the severity of anxiety. A score of 30-63 indicates severe anxiety, 17-29 moderate anxiety, 10-16 mild anxiety and 0-9 minimal anxiety. (NCT01362205)
Timeframe: Up to 28 days.
Intervention | units on a scale (Mean) |
---|---|
Dexmedetomidine | 30.3 |
Placebo | 21.6 |
The Beck Depression Inventory is a validated questionnaire used to measure severity of depression (min score 0, max score 63). The higher the score the greater the severity of depression. A score of 30-63 indicates severe depression, 19-29 moderate depression, 10-18 mild depression and 0-9 minimal depression. (NCT01362205)
Timeframe: Up to 28 days.
Intervention | units on a scale (Mean) |
---|---|
Dexmedetomidine | 26.5 |
Placebo | 21.4 |
The Mini Mental State Examination or Folstein test is a validated 30-point questionnaire used to measure cognitive impairment (min score 0, max score 30). A score of 24 points (out of a max of 30) indicates normal cognition, less than or equal to 9 points indicates severe impairment, 10-18 indicates moderate impairment and 19-23 mild impairment. (NCT01362205)
Timeframe: up to 28 days
Intervention | units on a scale (Mean) |
---|---|
Dexmedetomidine | 25.8 |
Placebo | 23.1 |
PTSD checklist consists of 17 questions graded on a scale of 1 to 5. The PTSD score is comprised from the sum of the scores 17 questions. The PTSD score has possible values from to 17 to 85 with higher values indicating greater symptom severity. (NCT01362205)
Timeframe: Up to 28 days
Intervention | units on a scale (Median) |
---|---|
Dexmedetomidine | 45.5 |
Placebo | 32.5 |
A hospital day is counted for any time on a calendar day the patient is admitted to the hospital. Hospital days are inclusive of ICU days. (NCT01362205)
Timeframe: up to 28 days
Intervention | days (Median) |
---|---|
Dexmedetomidine | 8.0 |
Placebo | 12.0 |
(NCT01362205)
Timeframe: up to 28 days in hours
Intervention | hours (Median) |
---|---|
Dexmedetomidine | 79.2 |
Placebo | 104.9 |
The Confusion Assessment Method (CAM)-ICU is a validated instrument used to detect the presence or absence of delirium in the ICU. A delirium free day is counted for any day a patient is negative by the CAM-ICU. The higher the number of CAM-ICU negative days indicates the more days a patient was able to think clearly. (NCT01362205)
Timeframe: up to 28 days
Intervention | days (Median) |
---|---|
Dexmedetomidine | 0.3 |
Placebo | 0.3 |
1 trial available for lorazepam and Hypertension
Article | Year |
---|---|
The effect of lorazepam on hypertension-associated anxiety: a double-blind study.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Double-Blind Method; Drug Evaluation; Female; Humans; Hypertens | 1978 |
13 other studies available for lorazepam and Hypertension
Article | Year |
---|---|
Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism.
Topics: Aged; Atrial Fibrillation; Basal Ganglia; Betacoronavirus; C-Reactive Protein; Catatonia; Coronaviru | 2020 |
Adjunctive Use of Ketamine for Benzodiazepine-Resistant Severe Alcohol Withdrawal: a Retrospective Evaluation.
Topics: Adult; Aged; Alcohol Withdrawal Seizures; Benzodiazepines; Blood Alcohol Content; Central Nervous Sy | 2018 |
Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
Topics: Aged; Anti-Dyskinesia Agents; Anticonvulsants; Antihypertensive Agents; Ataxia; Cerebellum; Dose-Res | 2009 |
Benzodiazepines in the acute management of seizures with autonomic manifestations: anticipate complications!
Topics: Autonomic Nervous System Diseases; Benzodiazepines; Child; Child, Preschool; Diazepam; Female; Human | 2011 |
Dexmedetomidine to facilitate drug withdrawal.
Topics: Alcohol Drinking; Blood Pressure; Cocaine-Related Disorders; Dexmedetomidine; Female; Heart Rate; Hu | 2003 |
Blood pressure and heart rate of students undergoing a medical licensing examination.
Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Anxiety; Blood Pressure; Educational Meas | 2004 |
Cocaine toxicity after laryngoscopy in an infant.
Topics: Administration, Topical; Anesthetics, Local; Cocaine; Humans; Hypertension; Infant; Laryngoscopy; Lo | 2006 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Foxy methoxy: a new drug of abuse.
Topics: 5-Methoxytryptamine; Adult; Anti-Anxiety Agents; Catalepsy; Emergency Medical Services; Hallucinatio | 2005 |
Effect of maternal lorazepam on the neonate.
Topics: Anti-Anxiety Agents; Apgar Score; Body Temperature; Female; Fetal Blood; Humans; Hypertension; Infan | 1981 |
A study of conjugation and drug elimination in the human neonate.
Topics: Anti-Anxiety Agents; Female; Humans; Hypertension; Infant, Newborn; Lorazepam; Male; Maternal-Fetal | 1981 |
Organic anxiety syndrome after withdrawal of atenolol.
Topics: Aged; Anxiety Disorders; Atenolol; Diltiazem; Humans; Hypertension; Lorazepam; Male; Substance Withd | 1994 |
Severe gamma-hydroxybutyrate withdrawal: a case report and literature review.
Topics: Adult; Akathisia, Drug-Induced; Anti-Anxiety Agents; Autonomic Nervous System Diseases; Emergencies; | 2000 |